In 2003, there seemed to be good reasons to leave weight-loss drugs out of the benefit, write Inmaculada Hernandez of the University of California, San Diego, and coauthors in their September 2023 editorial in the Journal of General Internal Medicine, Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform. When members of Congress worked on the Part D benefit, the drugs available on the market were known to have limited effectiveness and unpleasant side effects
This enzymatic process effectively prevents the transmission of lipid peroxides, thereby inhibiting ferroptosis
Medical Efficacy for Your Weight Loss Journey Recent clinical research confirms the effectiveness of these therapies in the treatment of obesity and metabolic disease
To achieve this, GLP-1s, along with the entire breadth of obesity treatments, must be prescribed with clinically rigorous behavior change programs, to give everyone a fair chance at sustained weight health.
